Company Profile
Amarin Corporation Stock Price, News & Catalysts
- Ticker:
- AMRN
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Ireland and listed in the U
Stock performance
11.26 USD (0.00%)
Close
Last updated: November 19, 2026
303M USD
Market cap
Why the stock is moving
As of Nov 19, 2026, AMRN was little changed and closed at $11.26. No new same-company headline was identified in the current news window.
Company overview
Cardiovascular Therapeutics Company
Amarin is a cardiovascular-focused pharmaceutical company built around prescription icosapent ethyl. Its commercial strategy combines a continuing U.S. presence with regional partners responsible for regulatory, market-access, and sales activities internationally.
VASCEPA and VAZKEPA
The product is sold as VASCEPA in the United States and VAZKEPA in many international markets. It is a highly purified prescription form of eicosapentaenoic acid developed for patients with elevated triglycerides and residual cardiovascular risk.
Cardiovascular Risk-Reduction Evidence
The REDUCE-IT outcomes study established the product's role in reducing major cardiovascular events in selected statin-treated patients. This evidence differentiates the medicine from nonprescription omega-3 supplements and supports its cardiovascular indication.
Partner-Led International Expansion
Amarin relies on commercial partners for most markets outside the United States. Recordati covers a broad European territory, while other partners manage China and additional regions, allowing the company to extend geographic reach without maintaining a fully owned global sales infrastructure.
U.S. Commercial and Supply Operations
In the United States, Amarin maintains product supply and commercial capabilities in a market that includes generic competition. The company continues to support branded demand while using international royalties, product sales, and partner economics to diversify the business.
Future catalysts
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Amarin Corporation (AMRN)?
Amarin Corporation (AMRN) most recently closed at 11.26 USD, a 0.00% move versus the previous session.
What is the market cap of Amarin Corporation (AMRN)?
Amarin Corporation currently has a market capitalization of 303M USD on BioPharmSignal.
What does Amarin Corporation do?
Cardiovascular Therapeutics Company Amarin is a cardiovascular-focused pharmaceutical company built around prescription icosapent ethyl. Its commercial strategy combines a continuing U.S. presence with regional partners responsible for regulatory, market-access, and sales activities internationally. VASCEPA and VAZKEPA The product is sold as VASCEPA in the...
On which exchange is AMRN stock listed?
Amarin Corporation (AMRN) is associated with NASDAQ, Ireland and listed in the U, Biopharma.
What is REDUCE-IT?
Cardiovascular Risk-Reduction Evidence The REDUCE-IT outcomes study established the product's role in reducing major cardiovascular events in selected statin-treated patients.
Which conditions is Amarin Corporation targeting with REDUCE-IT?
Amarin Corporation is associated with cardiovascular disease based on its company overview and current catalyst commentary.
What is Cardiovascular?
Cardiovascular Therapeutics Company Amarin is a cardiovascular-focused pharmaceutical company built around prescription icosapent ethyl.
What is Therapeutics?
Cardiovascular Therapeutics Company Amarin is a cardiovascular-focused pharmaceutical company built around prescription icosapent ethyl.
